DOCSLIB.ORG

UCB Integrated Annual Report 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
UCB Integrated Annual Report 2019 Hanneke, living with osteoporosis INTEGRATED ANNUAL REPORT 2019 Index We are UCB 3 Governance 58 Our purpose 4 1 Business conduct 60 Key figures 5 2 Risk management 63 We are UCB 6 3 Corporate governance statement (including remuneration report) 68 Letter to our stakeholders 8 Our business 11 Financials 108 Highlights 12 1 Business performance review 110 Our ambition for patients 13 2 Consolidated financial statements 123 Our performance 16 3 Notes to the consolidated financial statements 128 4 Responsibility statement 205 Patient Value Strategy 17 5 Statutory auditor’s report 206 1 Research and Development: innovating for patients 20 6 Abbreviated statutory financial statements of UCB SA 212 2 Immunology solutions: where deep insight and innovative science change lives 24 3 Neurology solutions: delivering effective and Data and reporting 215 meaningful solutions that patients truly value 27 People data 216 4 Patient access: enhancing sustainable value for patients, society and UCB through value-based GRI standards 221 access and pricing 30 Independent limited assurance report on the 5 Manufacturing and Supply: connecting UCB Integrated Annual Report 2019 234 development sciences with patient experience 31 6 Engaging and partnering with our stakeholders for sustainable patient value creation 33 Glossary of terms 236 References 238 People 37 Forward-looking statements 241 1 Strengthened organizational model 39 Financial calendar 242 2 Our empowered employees 40 Contact 242 3 Fostering an inclusive and diverse organization 42 4 Offering support for health and well-being, promoting safe behaviors 45 Communities & environment 47 1 Engaging with local communities 48 2 Improving epilepsy care in Africa and Asia 49 3 Minimizing our environmental footprint 53 Financial reporting Non-financial reporting Non-financial and financial reporting 2 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB Welcome to our 2019 Integrated Annual Report! Our 2019 Integrated Annual Report is a step on our journey to provide you with the best possible information on how UCB creates value for patients with severe diseases and for our societal stakeholders now and into the future. Today, more than ever, our 7 606 colleagues aspire to become the Patient Preferred Biopharma Leader! Jorge, Corinne, Yuko, Benedicte, UCB About this annual report This Integrated Annual Report 2019 includes the management Statement – Remuneration Report included –, Business report in accordance with article 12 of the Royal Decree of Performance Review and UCB’s Statement on non-financial 14 November 2007 relating to the obligations of issuers of information) is reported throughout all different sections of this financial instruments admitted to trading on a regulated market. Integrated Annual Report. This 2019 Integrated Annual Report All information required to be included in such management together with the materiality assessment have been prepared in report pursuant to articles 3:6 and 3:32 of the Belgian Code of accordance with the Global Reporting Standards: Core option. Companies and Associations (i.e. Corporate Governance Non-financial information is also audited by a third party. 3 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB | Our purpose Our purpose We create value for patients now and into the future. Victoria, living with psoriasis At UCB, we want to give people with severe diseases the With more than 90 years behind us, freedom to live their best lives. We work in a way that is we are looking to the future. sustainable for the patients who need our solutions, for the communities where we operate, and for society. 4 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB | Key figures Key figures 4 913 4 632 Revenue Number of assets in pipeline in € million 1 2 3 4 913 7 2018: 10 2018: 4 632 2018 2019 30.2 rEBITDA/ 29.1 R&D / revenue ratio revenue ratio 29.1% 26% 2018: 30.2% 2018: 25% 2018 2019 Employees 33% Women Executive level 7 606 UCB employees world-wide 38% 50% 50% Women Board Member Women Men UCB focuses on the following Reduction in UN Sustainable Development Goals: CO2 emissions −35% CO2 2018: −30% 5 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB | Our sites We are UCB A global biopharmaceutical company. U.K. Inspired by patients. Driven by science. At UCB, we are committed to bringing innovative therapies and Slough 714 employees solutions to address significant unmet needs for people with • Affiliate (9% of global) severe chronic diseases. UCB has its headquarters in Belgium • Research • Development 5 3 % / 47 % and our 7 606 employees across 36 markets put patients at the women / men heart of everything they do, driving our decisions and actions 97 million to bring innovative and differentiated solutions to people in our (2% of global net sales)1 two primary therapeutic areas of neurology and immunology. • ISO14001 certified • OHSAS 18001 certified • 93% electricity from renewable sources Switzerland Bulle 509 employees U.S. • Affiliate (7% of global) • Production 37 % / 6 3 % Atlanta, GA 1 403 employees women / men • Affiliate (18% of global) 40 million (1% of global net sales)1 Boston, MA 57% / 43% women / men • Research • ISO14001 certified • OHSAS18001 certified million 2 546 • Solar panels installed Raleigh, NC (54% of global net sales)1 • Development • 100% electricity from • 100% electricity from renewable sources Seattle, WA renewable sources • Research (Atlanta) Europe – others UCB has affiliates in Austria, Bulgaria, Czech Republic, Denmark, Finland, 600 employees 820 million 1 France, Greece, Hungary, Ireland, Italy, Netherlands, (8% of global) (17% of global net sales) Norway, Poland, Portugal, Romania, Slovakia, Spain, 62.5% / 37.5% Sweden women / men 6 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB | Our sites Japan Tokyo 469 employees • Affiliate (6% of global) • Development • Production 2 2 % / 7 8 % women / men Belgium Saitama 368 million • Production (8% of global net sales)1 Brussels 2 318 employees • ISO14001 certified • HQ (30% of global) • ISO45001 certified • Affiliate 4 6 % / 5 4% • 100% electricity from Braine-l’Alleud women / men renewable sources (production) • Production • Research 42 million 1 • Development (1% of global net sales) • ISO14001 certified (Braine) • Solar panels installed (Brussels and Braine) • 100% electricity from renewable sources Germany China Monheim 442 employees Shanghai 447 employees • Affiliate (6% of global) • Affiliate (6% of global) • Development • Development 60% / 40% 5 9 % / 41% women / men Zhuhai women / men • Production 333 million 137 million (7% of global net sales)1 (3% of global net sales)1 • 100% electricity from • ISO14001 certified renewable sources • OHSAS 18001 certified International markets – others UCB has affiliates in Australia, Brazil, Canada, Hong Kong, 704 employees 418 million India, Mexico, Russia, South Korea, (9% of global) (9% of global net sales)1 Taiwan, Turkey, Ukraine 5 4% / 4 6 % 1: Global net sales excluding hedging women / men 7 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB | Letter to our stakeholders Letter to our stakeholders Dear people living with severe chronic disease, dear shareholders, partners and colleagues, Welcome to our second Integrated Annual Report – thank you for An 8% annual revenue growth rate (CAGR) since 2014 and a continuing with us or joining our journey! boosted profitability (rEBITDA to revenue) from 18% in 2014 to 29% in 2019. Our aspiration to become the patient preferred biopharma leader – leveraging the different dimensions of our business to deliver Our strategic approach starts with an in-depth understanding of sustainable value for patients, our employees, society and our the patients, from biology to behavior rather than commencing shareholders – continues to guide us while we learn and adapt to from a pure scientific point of view. We want to understand the new and challenging environments. full impact of their disease which guides our scientists to develop original scientific hypothesis and translate them into innovative The implementation of our Patient Value Strategy in early 2015 solutions for specific patient populations. allowed us to positively impact 3.5 million patients’ lives in 2019 and deliver sustained company growth for the last five years: Jean-Christophe Tellier, Chief Executive Officer and Evelyn du Monceau, Chair of the Board By 2025, UCB aims to be a leader in specific patient populations strategy is the way to ensure UCB’s future success and sustainable and provide an increasing number of people with severe diseases growth. the freedom to live their best possible lives. Guided by our Patient In today’s world full of environmental and social challenges, we also Value Strategy and focusing on these patient populations, our acknowledge our responsibility to drive positive change. We are ambition is to deliver unique outcomes and the best experience committed to consider sustainability as a true business approach to all patients who need our solutions, in a way which is viable and we will focus our efforts on four areas that we believe are for patients, for society and for UCB. We are convinced that our critical to our long-term success and our contribution to society alongside our financial performance: continuously innovate to bring 8 UCB – INTEGRATED ANNUAL REPORT 2019 We are UCB | Letter to our stakeholders differentiated medicines to patients, improve patient access to our solutions, promote our employees’ safety, health and well-being and minimize our environmental footprint. UCB’s purpose is to create value for patients, now and into the future. Our ambition for patients relies on our innovation ability to bring differentiated solutions with unique outcomes that help specific patients achieve their life goals and that create the best individual experience for them. This also means ensuring access for all who need these solutions, in a way which is viable for patients, society and UCB. We believe that, to fulfil our ambition for patients, we must create the right conditions for our employees, the communities in which we operate, and our shareholders. We cannot do this alone and we embrace partnerships with other healthcare system stakeholders.
Load more

Recommended publications
  • UCB SA (Incorporated with Limited Liability in Belgium) As Issuer
    Base Prospectus dated 8 March 2021 UCB SA (incorporated with limited liability in Belgium) as Issuer EUR 5,000,000,000 Euro Medium Term Note Programme Due from one month from the date of original issue This base prospectus (the “Base Prospectus”) relating to the EUR 5,000,000,000 Euro Medium Term Note Programme (the “Programme”) of UCB SA, a limited liability company (société anonyme) incorporated under the laws of Belgium, having its registered office at Allée de la Recherche 60, B-1070 Brussels and registered with the Crossroads Bank for Enterprises under number 0403.053.608 (“UCB”, or the “Issuer”) is valid, for the purpose of the admission to trading and listing of the Notes (as defined below) on the regulated market of Euronext Brussels or on another regulated market in the European Economic Area (the “EEA”), for a period of twelve months from the date of approval. Any Notes issued under the Programme are issued subject to the provisions set out herein. Under the Programme, the Issuer, subject to compliance with all relevant laws, regulations and directives, may from time to time issue Euro Medium Term Notes (the “Notes”) as may be agreed between the Issuer and the relevant Dealer (as defined below). The minimum Specified Denomination of Notes shall be EUR 100,000 (or its equivalent in other currencies).The maximum aggregate nominal amount of Notes outstanding will not at any time exceed EUR 5,000,000,000 (or the equivalent in other currencies). This Base Prospectus has been approved as a base prospectus for the purposes of Article 8 of Regulation 2017/1129 (as amended, the “Prospectus Regulation”) on 8 March 2021 by the Belgian Financial Services and Markets Authority (the “FSMA”) in its capacity as competent authority in accordance with Article 20 of the Prospectus Regulation.
    [Show full text]
  • Integrated Annual Report 2020
    Amber, living with psoriasis INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE INTEGRATED ANNUAL REPORT 2020 ADAPTING FOR BETTER CARE Welcome to our Integrated Annual Report 2020! Our Integrated Annual Report 2020 – Adapting for Better Care – aims to provide all interested stakeholders with the best pos- sible information on how UCB is creating value for patients with severe diseases and about how we care for our employees, for communities, and for our planet, now and into the future. About this report This Integrated Annual Report 2020 includes the management report in accordance with article 12 of the Royal Decree of 14 November 2007 relating to the obligations of issuers of finan- cial instruments admitted to trading on a regulated market. All information required to be included in such management report pursuant to articles 3:6 and 3:32 of the Belgian Code of Com- panies and Associations (i.e. Corporate Governance Statement – Remuneration Report included -, Business Performance Review and UCB’s Statement on extra-financial1 information) is reported throughout all different sections of this Integrated Annual Re- port. This Integrated Annual Report together with the materiality assessment have been prepared in accordance with the Global Reporting Standards core option and extra-financial information is audited by a third party. 1 ‘Extra-financial’ is the term used by UCB for information commonly referred to as ‘non-financial’. UCB | Integrated Annual Report 2020 3 Index Key Figures 6 UCB At a Glance 8 Letter to our stakeholders
    [Show full text]
  • Dynavax Announces Full Enrollment of Phase II/III AIC Trial
    Dynavax Announces Full Enrollment of Phase II/III AIC Trial BERKELEY, Calif., May 19 /PRNewswire-FirstCall/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative products to treat and prevent allergies, infectious diseases and chronic inflammatory diseases, today announced that its Phase II/III clinical trial of AIC for ragweed allergy, which started in late February 2004, has been fully enrolled. The double blind, placebo controlled study involves 462 subjects at 30 sites in the U.S. and will be completed over the next 18 months. The immunization schedule, consisting of six injections over six weeks, will be completed by June. The clinical trial is being conducted in collaboration with UCB Pharma, a European pharmaceutical company that markets XYZAL® and developed ZYRTEC®, the leading prescription anti- allergy drug worldwide. Dynavax and UCB signed a global licensing and commercialization agreement covering ragweed and grass allergy immunotherapies in February 2004. The primary endpoint of the Phase II/III ragweed study will be nasal symptoms scores after the second ragweed season in the late summer and early fall of 2005, with secondary endpoints assessing symptoms, medication use and quality of life in both the first and second year. A blinded interim analysis will be made in late 2004 to assess safety and the appropriateness of commencing a one-year Phase III trial in early 2005. "The collaboration with UCB has been very effective, with both organizations working diligently to advance our ragweed program," said Dr. Dino Dina, president and CEO of Dynavax. "The rapid enrollment of our ragweed trial, particularly given its size and stringent enrollment criteria, is an early indication of the level of interest that both investigators and patients have in this therapy.
    [Show full text]
  • Lamotrigine Orally Disintegrating Tablet
    UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2021 P 3001-14 Program Step Therapy - Anticonvulsants Medication/Therapeutic Anticonvulsants – Class Depakote®, Depakote ER®, Felbatol, Keppra® , Keppra® XR®, Lamictal®, Lamictal XR®, Lamictal ODT®, lamotrigine extended-release, lamotrigine orally disintegrating tablet, Lyrica, Mysoline, Neurontin®, Onfi, Oxtellar™ XR*, Qudexy XR* (brand and authorized generic), Sabril, Spritam*, Topamax®, Trileptal®, Trokendi® XR*, Zonegran® P&T Approval Date 8/2010, 11/2010, 11/2011, 2/2013, 11/2013, 4/2014, 7/2014, 11/2014, 4/2015, 1/2016, 6/2016, 6/2017, 9/2018, 9/2019, 10/2020, 6/2021 Effective Date 9/1/2021; Oxford only: N/A 1. Background Step Therapy programs are utilized to encourage use of lower cost alternatives for certain therapeutic classes. a. Multi-Source Brand Products This program requires a member to try the A-rated generic prior to receiving coverage for Depakote, Depakote ER, Felbatol, Keppra, Keppra XR, Lamictal, Lamictal ODT, Lamictal XR, Lyrica, Mysoline, Neurontin, Onfi, Sabril, Topamax, Trileptal and Zonegran. There will be exceptions for members with a documented diagnosis of a seizure disorder. For members with a claim for at least a 14 day supply of the A-rated generic in the previous 6 months, the prescription will process automatically. b. Modified Release Products This program requires a member to try levetiracetam immediate release, levetiracetam extended-release, levetiracetam solution, lamotrigine immediate release, divalproex sodium delayed release, Depakote delayed release, generic valproic acid, Depakene formulations, Depakote sprinkles, divalproex sodium sprinkles, oxcarbazepine or Trileptal prior to coverage of their respective modified release formulations: lamotrigine extended-release, lamotrigine orally disintegrating tablet, Oxtellar XR*, Qudexy XR*, Spritam and Trokendi XR*.
    [Show full text]
  • Portfolio of Investments
    PORTFOLIO OF INVESTMENTS Variable Portfolio – Partners International Value Fund, September 30, 2020 (Unaudited) (Percentages represent value of investments compared to net assets) Investments in securities Common Stocks 97.9% Common Stocks (continued) Issuer Shares Value ($) Issuer Shares Value ($) Australia 4.2% UCB SA 3,232 367,070 AMP Ltd. 247,119 232,705 Total 13,350,657 Aurizon Holdings Ltd. 64,744 199,177 China 0.6% Australia & New Zealand Banking Group Ltd. 340,950 4,253,691 Baidu, Inc., ADR(a) 15,000 1,898,850 Bendigo & Adelaide Bank Ltd. 30,812 134,198 China Mobile Ltd. 658,000 4,223,890 BlueScope Steel Ltd. 132,090 1,217,053 Total 6,122,740 Boral Ltd. 177,752 587,387 Denmark 1.9% Challenger Ltd. 802,400 2,232,907 AP Moller - Maersk A/S, Class A 160 234,206 Cleanaway Waste Management Ltd. 273,032 412,273 AP Moller - Maersk A/S, Class B 3,945 6,236,577 Crown Resorts Ltd. 31,489 200,032 Carlsberg A/S, Class B 12,199 1,643,476 Fortescue Metals Group Ltd. 194,057 2,279,787 Danske Bank A/S(a) 35,892 485,479 Harvey Norman Holdings Ltd. 144,797 471,278 Demant A/S(a) 8,210 257,475 Incitec Pivot Ltd. 377,247 552,746 Drilling Co. of 1972 A/S (The)(a) 40,700 879,052 LendLease Group 485,961 3,882,083 DSV PANALPINA A/S 15,851 2,571,083 Macquarie Group Ltd. 65,800 5,703,825 Genmab A/S(a) 1,071 388,672 National Australia Bank Ltd.
    [Show full text]
  • 205836Orig1s000 205837Orig1s000 205838Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 205836Orig1s000 205837Orig1s000 205838Orig1s000 ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS EXCLUSIVITY SUMMARY NDA #: NDA 205836 (oral tablets), NDA 205837 (injection 10 mg/mL) NDA 205838 (oral solution 10 mg/mL) SUPPL # HFD # Trade Name: BRIVIACT Generic Name: BRIVIACT (brivaracetam); 10, 25, 50, 75, and 100 mg oral tablets; injection (10 mg/mL); and oral solution (10 mg/mL) Applicant Name: UCB, Inc. Approval Date, If Known: February 19, 2016 PART I IS AN EXCLUSIVITY DETERMINATION NEEDED? 1. An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission. a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement? YES X NO If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3,SE4, SE5, SE6, SE7, SE8 505(b)(1) c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.") YES X NO If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study. If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data: Reference ID: 3888400 Page 1 d) Did the applicant request exclusivity? YES X NO New moiety exclusivity requested If the answer to (d) is "yes," how many years of exclusivity did the applicant request? Applicant did not specify.
    [Show full text]
  • Celltech, a Sound Strategic Acquisition Neutral
    UCB 8 June 2004 Celltech, a sound strategic acquisition Pharmaceuticals & Biotechnology Current price € 39.90 Neutral Belgium Target price € 42.00 Rating unchanged 118 FY/e 31.12 2003 2004E 2005E 2006E 40 Sales (€ m) 2,966 3,107 3,492 3,885 110 36 EBITDA (€ m) 647 672 810 948 102 Pre-Tax* (€ m) 485 453 486 621 32 94 Adj EPS* (€) 2.32 2.21 2.46 3.09 28 86 EPS (€) 2.32 1.83 1.70 2.32 DPS (€) 0.82 0.85 0.88 0.92 24 78 P/E* (x) 17.2 18.1 16.2 12.9 20 70 Yield (%) 2.1 2.1 2.2 2.3 JJSONJFMM Price Rel. to index (RHS) EV/EBITDA (x) 9.2 12.1 10.1 8.7 Source: Thomson Financial Datastream Source: KBC Securities *Adjusted for goodwill and exceptionals Reuters UCBBt.BR Bloomberg UCB BB UCB’s share price hasn’t stopped soaring since the www.ucb-group.com acquisition of Celltech. Although we are positive about this Market Cap € 5,823m strategic acquisition, we think that the upside potential is Shares outst. 145.9m now virtually exhausted. Volume (daily) € 10.6m Free float 59% • From a strategic standpoint, Celltech’s acquisition is an enormous step forward, reinforcing UCB’s Pharma pipeline Next corporate event and management team. But the road to positive returns is General Assembly FY03 on 8 June 2004 still long and risky, so UCB still deserves a discount to Performance over 1m 3m 12m average Pharma ratios. Absolute 14% 31% 45% In technical terms, the merger should be positive as the Rel.
    [Show full text]
  • FORM 8-K PDL Biopharma, Inc
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 2, 2011 PDL BioPharma, Inc. (Exact name of Company as specified in its charter) 000-19756 (Commission File Number) Delaware 94-3023969 (State or Other Jurisdiction of (I.R.S. Employer Identification No.) Incorporation) 932 Southwood Boulevard Incline Village, Nevada 89451 (Address of principal executive offices, with zip code) (775) 832-8500 (Company’s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions: ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Item 8.01 Other Events. PDL BioPharma, Inc. Resolves Patent Disputes with UCB Pharma SA On February 7, 2011, PDL BioPharma, Inc. (“PDL”) and UCB SA, on behalf of its affiliate UCB Pharma S.A. (“UCB”), jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between the parties, including those relating to UCB’s pegylated humanized antibody fragment, Cimzia® (certoluzimab pegol), and PDL’s Queen et al.
    [Show full text]
  • Schedule of Investments (Unaudited) Ishares MSCI EAFE International Index Fund March 31, 2021 (Percentages Shown Are Based on Net Assets)
    Schedule of Investments (unaudited) iShares MSCI EAFE International Index Fund March 31, 2021 (Percentages shown are based on Net Assets) Security Shares Value Security Shares Value Common Stocks Australia (continued) Westpac Banking Corp............................... 1,587,920 $ 29,454,234 Australia — 7.1% WiseTech Global Ltd................................. 63,926 1,422,472 (a) 93,913 $ 7,334,984 Afterpay Ltd. ...................................... Woodside Petroleum Ltd. ............................ 423,054 7,732,535 AGL Energy Ltd. 271,208 1,993,726 .................................... Woolworths Group Ltd. .............................. 556,331 17,326,498 AMP Ltd............................................. 1,491,250 1,437,778 Ampol Ltd. .......................................... 108,096 2,023,613 520,693,776 APA Group.......................................... 518,754 3,960,967 Austria — 0.2% Aristocrat Leisure Ltd. ............................... 252,669 6,628,931 Erste Group Bank AG ............................... 123,031 4,168,081 ASX Ltd. ............................................ 86,407 4,677,172 OMV AG ............................................ 64,777 3,282,719 Aurizon Holdings Ltd................................. 823,283 2,446,565 Raiffeisen Bank International AG(a) ................... 65,199 1,431,303 AusNet Services .................................... 851,318 1,189,926 Verbund AG......................................... 30,270 2,198,784 Australia & New Zealand Banking Group Ltd. ......... 1,248,802 26,812,369 voestalpine
    [Show full text]
  • 2015 Annual Report PROFILE
    ASKING MORE 2015 Annual Report PROFILE SUSTAINABLE VALUE CREATION Our strategy is a virtuous circle in which positive actions interact to create enriching contributions centered around a single goal: creating a future with more potential. MORE talent BY ACTING RESPONSIBLY BY INNOVATING Asking from chemistry MORE MORE innovative commitment sustainable solutions BY CONTRIBUTING TO SOCIETY € 12.4 bn 30,900 145 NET SALES EMPLOYEES INDUSTRIAL SITES AND A PRESENCE IN 53 COUNTRIES Who we are An international chemical and advanced materials company, Solvay assists its customers in innovating, developing, and delivering high-value, sustainable products and solutions that consume less energy and reduce CO2 emissions, optimize the use of resources and improve the quality of life. Solvay serves diversified global end markets including automotive and aerospace, consumer goods and healthcare, energy and environment, electricity and electronics, building and construction, as well as industrial applications. Solvay is headquartered in Brussels with about 30,000 employees spread across 53 countries. It generated pro forma net sales of €12.4 bn in 2015, with 90% made from activities where it ranks among the world’s top 3 players. Solvay SA (SOLB.BE) is listed on Euronext in Brussels and Paris (Bloomberg: SOLB.BB – Reuters: SOLB.BR). SOLVAY 2015 ANNUAL REPORT Asking from chemistry The 2015 Solvay Annual Report takes you inside our journey of transformation. We’re implementing an ambitious strategy to build a new model of sustainable chemistry that addresses the environmental and societal factors impacting our world. The challenge we have set ourselves is to achieve these strategic targets while continuing to drive value creation and profitable growth in a responsible way.
    [Show full text]
  • Ceo of Biopharma Company Ucb to Chair Imi Governing Board
    FOR IMMEDIATE RELEASE IMI/KDR/DOC/2012-557 PRESS RELEASE CEO OF BIOPHARMA COMPANY UCB TO CHAIR IMI GOVERNING BOARD Roch Doliveux confirms industry’s commitment to unique EU public-private partnership BRUSSELS (Belgium), 7 March 2012 – The Innovative Medicines Initiative (IMI) announced today that Roch Doliveux, CEO of the biopharmaceutical company UCB, has been appointed Chairman of the Governing Board of IMI. IMI is a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA). UCB has been involved in IMI since its initiation, and Roch Doliveux has been a member of the IMI Governing Board since May 2010. IMI currently funds 30 projects with a combined budget of around €600 million and covering drug safety and efficacy, knowledge management, and education & training. Michel Goldman, Executive Director of IMI said: ‘IMI will greatly benefit from the leadership and patient-centric perspective of Roch Doliveux. As Chair of the IMI Governing Board, Roch will be in a unique position to move forward his vision for the future of the pharmaceutical industry based on open innovation and precompetitive research. The early achievements of the ongoing IMI projects demonstrate that this new model based on public-private partnership is already successful.’ Roch Doliveux, CEO of UCB and member of the Board of the European Federation of Pharmaceutical Association (EFPIA) says: ‘The biopharmaceutical industry has reached an inflection point where public-private partnerships, bringing academic and industry knowledge together, are paving the way to better respond to new healthcare needs and bring safer, more efficacious and cost-effective treatments to patients.
    [Show full text]
  • Report to Shareholders and Society Who We Are
    2009 Report to Shareholders and Society Who we are Umicore is a materials technology group. Its activities are centred on four business areas: Advanced Materials, Precious Metals Products and Catalysts, Precious Metals Services and Zinc Specialties. Each business area is divided into market-focused business units, be it in products that are essential to everyday life or those at the cutting edge of new technological developments. Umicore focuses on application areas where it knows its expertise in materials science, chemistry and metallurgy can make a real difference. Umicore generates approximately 50% of its revenues and spends approximately 80% of its R&D budget in the area of clean technology, such as emission control catalysts, materials for rechargeable batteries and photovoltaics, fuel cells, and recycling. application know-how chemistry metals material science material metallurgy solutions recycling The Umicore approach to materials technology We are a member of the World Business Council for Sustainable Development. We are part of the FTSE4Good Index, have been awarded a “best in class” rating by Storebrand Socially Responsible Investments and are part of the Kempen / SNS Smaller Europe SRI Index. 2009 Report to shareholders and society Economic Report p. 18 Environmental Report p. 36 Social Report p. 54 Financial statements p. 75 Governance Report p. 120 What we believe We believe that materials have been a key element in furthering the progress of mankind, that they are at the core of today’s life and will continue to be enablers for future wealth creation. We believe that metal related materials have a vital role, as they can be efficiently and infinitely recycled, which makes them the basis for sustainable products and services.
    [Show full text]